Dr. Agarwal's Health Care Ltd. (AGARWALEYE) AI Stock Analysis

• Market Cap: ₹134.41B
• Dividend Yield: N/A
• Average Volume (3M): 13.83K
• Price to Earnings (P/E): 118.8
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 4,214
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.10
• Shares Outstanding: 316,807,500
• 10 Day Avg. Volume: 7,500
• 30 Day Avg. Volume: 13,832
• PEG Ratio: 43.43
• Price to Book (P/B): 7.19
• Price to Sales (P/S): 7.85
• P/FCF Ratio: 589.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 4.02
• Revenue Forecast (FY): ₹20.63B

• Rating: 73 Outperform
• Price Target: ₹473.00 ▼(-5.40% Downside)
• Action: Reiterated Date: 10/23/25
• Date: Action: Reiterated 10/23/25

Dr. Agarwal's Health Care Ltd. demonstrates strong financial performance with significant revenue and profit growth, which is the most significant factor in the overall score. Technical analysis indicates positive momentum, though caution is advised due to overbought signals. The lack of valuation metrics introduces some uncertainty, slightly impacting the overall score.

Positive Factors

Revenue & Profit Growth

Consistent revenue and profit growth indicate durable demand for ophthalmology services and scalable operations across centers. Sustained top-line expansion supports reinvestment in facilities and talent, enhancing long-term service breadth and competitive positioning in eye care.

Cash Generation

Strong operating cash flow and expanding free cash flow provide internal funding for capex, expansion and debt servicing without reliance on external capital. Reliable cash generation boosts financial flexibility and resilience through multi-year growth phases and investment cycles.

Margin Improvement

Improving gross and operating margins reflect efficiency gains in clinical operations and cost control. Sustainable margin expansion increases cash conversion and ability to invest in higher-value procedures, strengthening long-term profitability per patient treated.

Negative Factors

Moderate Leverage

A moderately high debt-to-equity ratio raises financial flexibility risks, increasing interest burden and sensitivity to rate moves. Persistent leverage can constrain capital allocation, making the company more vulnerable to revenue disruptions or higher financing costs over the medium term.

Profit Margin Volatility

Volatile net margins reduce earnings predictability and complicate multi-period planning. If variability stems from financing or expense spikes, it can erode free cash flow in downturns and limit the company's ability to steadily fund expansion or absorb unexpected clinical or input-cost shocks.

Execution & Scale Risk

Growth dependent on adding centers and increasing patient volumes is capital intensive and execution-sensitive. Lack of disclosed same-store metrics and payer-mix detail raises uncertainty about organic demand sustainability and the returns profile of new openings over the medium term.

Dr. Agarwal's Health Care Ltd. Business Overview & Revenue Model

Company Description

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.

How the Company Makes Money

The company primarily makes money by delivering clinical ophthalmology services through its hospital/clinic network. Key revenue streams include: (1) Surgical and procedure revenue: fees from ophthalmic surgeries and interventional procedures (e.g., cataract and other specialized eye surgeries), typically comprising surgeon/professional fees, hospital/OT charges, consumables, and lens/implant-related billing where applicable. (2) Outpatient services: revenue from doctor consultations, follow-up visits, diagnostics and imaging (e.g., refraction tests and ophthalmic diagnostics), and minor in-clinic procedures. (3) Sale of related products and ancillary services: income from optical dispensing (spectacles/frames/lenses) and other patient support offerings available at centers; if specific product categories beyond optical are not publicly detailed, they are treated as part of ancillary center-based revenue. (4) Payer mix and payment sources: earnings are supported by direct patient payments and reimbursements from third-party payers (e.g., insurers and corporate/TPA arrangements) where such coverage applies; specific payer split percentages are null. (5) Network expansion and operating leverage: revenue growth is driven by increasing patient footfall and scaling the number of centers; exact center count and same-store metrics are null. Significant partnerships or named contractual arrangements are null where not specifically disclosed in available public information.

Dr. Agarwal's Health Care Ltd. Financial Statement Overview

Summary

Dr. Agarwal's Health Care Ltd. presents a solid financial profile with strong revenue and profit growth, efficient operations, and healthy cash flow generation. The company maintains a strong equity base, though careful monitoring of debt levels is advisable.

Income Statement

Dr. Agarwal's Health Care Ltd. demonstrates strong revenue growth, with a substantial increase from 2022 to 2025. The gross profit margin is healthy, reflecting efficient cost management. The company has improved its EBIT and EBITDA margins over the years, indicating enhanced operational efficiency. However, the net profit margin shows some volatility, which could be due to fluctuating expenses or financing costs.

Balance Sheet

The balance sheet reveals a robust equity position with a growing stockholders' equity. The debt-to-equity ratio is moderately high, which suggests reliance on debt financing but is not alarming given the equity growth. Return on Equity (ROE) has improved, demonstrating effective use of equity to generate profits. However, the company should monitor its leverage to mitigate potential risks.

Cash Flow

Cash flow analysis shows consistent positive operating cash flow, supporting the company's operations and growth. The free cash flow has grown over the years, though there are fluctuations due to capital expenditures. The operating cash flow to net income ratio indicates strong cash generation relative to reported earnings, underscoring operational health.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	18.77B	17.11B	13.32B	10.16B	6.95B	4.71B
Gross Profit	8.87B	9.91B	3.85B	2.96B	1.91B	2.87B
EBITDA	5.23B	4.99B	4.50B	2.84B	1.96B	428.70M
Net Income	1.15B	834.60M	1.02B	940.97M	376.94M	-554.78M
Balance Sheet
Total Assets	37.86B	36.72B	27.83B	18.25B	10.26B	7.87B
Cash, Cash Equivalents and Short-Term Investments	3.97B	5.22B	5.87B	1.61B	996.21M	552.12M
Total Debt	9.83B	9.61B	9.68B	8.57B	6.19B	4.69B
Total Liabilities	17.67B	17.45B	13.89B	11.66B	7.92B	5.88B
Stockholders Equity	19.31B	18.67B	13.48B	6.30B	2.12B	1.84B
Cash Flow
Free Cash Flow	495.00M	227.90M	1.14B	753.05M	937.40M	-273.94M
Operating Cash Flow	2.62B	3.31B	3.46B	2.33B	1.64B	991.59M
Investing Cash Flow	-1.36B	-7.54B	-9.14B	-5.09B	-1.55B	-365.69M
Financing Cash Flow	-1.32B	4.14B	5.53B	3.03B	354.33M	-371.07M

Dr. Agarwal's Health Care Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 500.00
• 50DMA: Positive
• 100DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AGARWALEYE, the sentiment is Positive. The current price of 500 is below the 20-day moving average (MA) of 508.88, below the 50-day MA of 502.56, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.68 indicates Positive momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 47.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AGARWALEYE.

Dr. Agarwal's Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGARWALEYE	73 Outperform	₹134.41B	118.77	―	―	―	―
MARKSANS	71 Outperform	₹76.92B	18.03	―	0.44%	14.80%	1.35%
HCG	67 Neutral	₹81.07B	-247.47	―	―	17.58%	-38.20%
JLHL	67 Neutral	₹82.96B	53.67	―	0.14%	18.40%	7.30%
RAINBOW	66 Neutral	₹113.44B	46.21	―	0.22%	9.91%	9.57%
METROPOLIS	61 Neutral	₹91.09B	60.35	―	0.21%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Dr. Agarwal's Health Care Ltd. Corporate Events

Dr. Agarwal’s Health Care Grants 4.44 Lakh ESOPs Under 2022 Scheme

Dr. Agarwal’s Health Care Limited has granted 444,500 stock options under its Employees Stock Option Scheme 2022 to eligible employees of the company and its subsidiaries, following approval by the Nomination and Remuneration Committee at its 3 February 2026 meeting. The options, which correspond to 444,500 equity shares of ₹1 each, will be priced based on fair market value at the grant date with the possibility of up to a 20% discount, subject to a floor at par value, and will vest in four equal annual tranches over four years, reflecting the company’s effort to strengthen employee alignment and retention in line with SEBI’s share-based benefit regulations.

Dr. Agarwal’s Health Care Gets Clean Monitoring Report on IPO Proceeds Utilisation

Dr. Agarwal’s Health Care Limited has disclosed that the independent Monitoring Agency, ICRA Limited, has confirmed there is no deviation in the company’s use of proceeds from its Initial Public Offer for the quarter ended December 31, 2025. The monitoring report, filed under SEBI regulations and made available on the company’s website, states that IPO funds have been utilized in line with the stated objects of the issue, reinforcing governance standards and offering reassurance to investors and regulators regarding the company’s capital deployment and compliance practices.

Dr. Agarwal’s Health Care Sets Board Meet and Analyst Call for Q3 FY26 Results

Dr. Agarwal’s Health Care Limited has scheduled a board meeting on February 3, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and has maintained a trading window closure in line with its insider trading prevention code until 48 hours after the results are announced. The company will follow this with an earnings and analyst conference call on February 4, 2026, where senior management, including the CEO, CFO and Head of Investor Relations, will discuss the financial performance with investors and analysts, underscoring its emphasis on transparency, regulatory compliance and active engagement with the capital markets.